GLP-1 Is Restructuring Grocery. Your Portfolio Does Not Know It Yet.

A drug became a demand signal

For most of its history, grocery demand moved with income, weather, and price. It now moves with a prescription too. About one in eight US adults is taking a GLP-1 medication, the class that includes Ozempic, Wegovy, Mounjaro, and Zepbound, double the share of eighteen months before.¹ Almost one in five has taken one at some point.¹ The households using them already account for close to a quarter of all US households, and on one projection they will drive 35 percent of all US food and drink units sold by 2030.²

You do not have to believe that exact number to take it seriously. A force that touched a few percent of adults two years ago and a quarter of households now is not waiting for your next planning cycle. Walmart spotted it early in its own data, telling reporters that its GLP-1 shoppers were buying fewer units and slightly fewer calories than otherwise similar customers.³ It is already in your volumes, whether or not your category model has a line for it.

It does not hit the basket evenly

The headline is that these shoppers buy less. The commercial story sits underneath, in what they swap in.

The cleanest read comes from a peer-reviewed study run on a 150,000-household purchase panel, matched against who was actually starting the drugs.⁴ Within six months of starting, grocery spending fell about 5 percent, and more than 8 percent among higher-income households. Spending at fast food and other quick-service outlets fell about 8 percent. Underneath that, savory snacks dropped around 10 percent, with sweets and baked goods close behind, while yogurt, fresh fruit, nutrition bars, and meat snacks rose.⁴ A wider tracker put protein shakes up 38 percent and so-called superfoods up 58 percent among these households.⁵

So a calorie leaves the basket and a gram of protein takes its place. If your portfolio sits on the wrong side of that line, the category total you report will look like a soft patch when your heaviest-buying households are really just buying something else.

The pack you optimised is the wrong pack

This gets specific for anyone who manages a range. A GLP-1 user eats less at a sitting. The large sharing bag and the multipack, the formats built to win on price per gram, are exactly the ones this shopper no longer finishes. The rule that the bigger pack is always the better deal quietly stops holding.

It is already showing up on shelf. Conagra put a "GLP-1 Friendly" badge on more than two dozen Healthy Choice meals, built around portion control and protein.⁶ General Mills and others have pushed protein-forward versions of mainstream products. The move that works is not a health sub-brand bolted on the side. It is re-cutting the core range for an occasion that is changing shape.

The mix damage compounds

The reason this reaches the profit line, and not just the volume line, is which categories are losing. Snacks, confectionery, and indulgent frozen meals are often the margin-rich end of a food portfolio. They are also the categories the data shows falling hardest among GLP-1 households.⁴ One large advisory estimate puts up to 12 billion dollars of US snack sales at risk over the next decade, split fairly evenly between salty and sweet.⁷ Losing volume in your best-margin categories, to a buyer group that is growing, is a mix headwind that compounds quarter after quarter.

The mechanism is worth seeing in numbers, because it points straight at the fix.

Take a snack you sell as a 300 gram pack at 3.00, costing 1.80 to make. That is 1.20 of gross profit on a 40 percent margin. Your GLP-1 shopper now finds 300 grams too much and simply stops buying it. The occasion, and the 1.20, are gone. Now offer that same shopper a 150 gram, protein-forward pack at 2.10, costing 1.05. That is 1.05 of gross profit on a 50 percent margin. You have kept just under 90 percent of the profit on half the grams, at a higher margin, on an occasion you would otherwise have lost completely. The smaller pack is dearer per gram, and for this shopper that is fair, because they are paying for enough rather than for the most.

What could make this smaller

This is not an overnight collapse, and anyone selling it as one is overselling. More than half of the people who start a GLP-1 stop within a year, on the evidence of a large national study.⁸ Most users say the drugs are hard to afford.¹ Those two facts are why Mondelez's chief executive has put the likely hit at 1 to 1.5 percent of volume over ten years, a rounding error next to the headlines.⁹ He may be right about the average.

Two things cut against the comfortable reading. The installed base is still growing every quarter even with people dropping out, and almost one in five adults has now used one of these drugs at least once.¹ And some of the change holds: produce and a few other categories stay elevated even after people come off the drug, and half of those who stop expect to go back on it.² A churning user base is still a larger and differently shaped one each year.

What would I do on Monday?

Three moves. First, score your portfolio for exposure: which of your volume, and more to the point your profit, sits in the categories the data shows GLP-1 households cutting, and which sits in the ones they are feeding. Second, build the smaller, protein-dense pack for your most exposed line before you lose the occasion, and price it for value per nutrient, not value per gram. Third, rebias your innovation and your promotion toward the growing side, and stop pouring depth discounts into big calorie-dense packs aimed at a shopper who is, quietly, leaving.

A drug changed what your best customers want for dinner. That is not in anyone's elasticity model, and it does not need to be in a headline to already be in your numbers.

References